Factor Therapeutics Ltd (ftt) Logo

Factor Therapeutics Ltd (FTT)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

FTT Chart

FTT's Principal Activity is the identification and diligence of potential new business opportunities for the Company.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +156.89%
vs ASX 200 (1yr) +122.03%

Size

Market Capitalisation
ASX Rank 2260 of 2,560
Sector Rank 174 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies SIL / CAU / MGZ
EPS $0.00
DPS $0.00
NTA per share $0.00

Broker Consensus

FTT is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

Factor Therapeutics (FTT, formerly Tissue Therapies Limited) is a clinical-stage life sciences company. It develops treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. FTT is commercialising VF-001, a technology for cell based therapies. FTT is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate.

Incorporation Details

Incorporated Tissue Therapies Limited was incorporated on 6 September 2002 in Queensland

Corporate Details

Head Office
Website -
Registry Link Market Services
Auditor PKF BRISBANE AUDIT
Date Listed 19 Mar 2004

Upcoming Calendar

Date Event
28/07/2021 Report (Interim)
23/02/2022 Report (Prelim)
23/02/2022 Report (Annual)

Dividend History

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr David Lionel Brookes Non-Executive Director,Non-Executive Chairman Apr 2019 Director Bio icon

Dr David Lionel Brookes

Non-Executive Director,Non-Executive Chairman

Dr Brookes has experience in the health and biotechnology industries and is currently a Non-Executive director of Anatara Ltd (ASX:ANR) and TALi Digital Limited (ASX:TD1). He has previously been a director of several other ASX listed biotechnology companies, most recently as the Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc in June 2018. Until its acquisition in January 2021, Dr Brookes was Non-Executive Chairman of the Better Medical Group, and maintains roles as a clinician and a biotechnology industry consultant. He is Member of Risk Management Committee.

Mr John Michailidis Non-Executive Director Feb 2017 Director Bio icon

Mr John Michailidis

Non-Executive Director

Mr Michailidis is currently the Managing Director for TEVA Australia/NZ and brings over 30 years of commercial pharmaceutical experience to Factor, most recently as Managing Director for TEVA, Australia and New Zealand. His career has ranged from global franchise and regional executive leadership roles with F. Hoffman - La Roche (Roche) to CEO experience with growth-stage biopharmaceutical companies, such as AviPep and Orphan Australia (acquired by Sigma). He is Chair of Risk Management Committee.

Ms Melanie Farris Company Secretary Sep 2016
Dr Christian Peter Behrenbruch Non-Executive Director Oct 2015 Director Bio icon

Dr Christian Peter Behrenbruch

Non-Executive Director

Dr Behrenbruch has over 15 years of C-level leadership experience in the medtech, biotechnology and healthcare IT space, and has significant experience as a director of commercial and non-profit organisations. His former CEO/Director-level appointments include Mirada Solutions (now Siemens Plc), Fibron Technologies and ImaginAb, Inc. He is a former director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd, Radius Health Ltd (now Adaptix), Cell Therapies P/L (Peter MacCallum Cancer Centre) and the Oncidium Foundation. He is currently the Managing Director and CEO of Telix Pharmaceuticals Limited (ASX:TLX), Chairman of Monash Engineering and IT Foundation Board and is a Professorial Fellow at Monash University.

Director Transactions

FTT directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
19/04/18 Cherrell Hirst Issued 474,830 $0.04 $18,993 Rights issue
19/04/18 Christian Behrenbruch Issued 408,164 $0.04 $16,327 Rights issue
19/04/18 John Michailidis Issued 527,432 $0.04 $21,097 Rights issue

Director Interests

The current holdings of FTT directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
John Michailidis 31/12/2020 N/A 527,432 1,000,000 N/A
Christian Behrenbruch 31/12/2020 N/A 3,265,306 3,000,000 N/A
David Brookes 31/12/2020 2,500,000 10,300,000 N/A N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Jan 13, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Calama Holdings Pty Ltd 40,000,000 3.84%
GP Securities Pty Ltd 28,607,989 2.74%
Citicorp Nominees Pty Limited 24,261,921 2.33%
Yelwac Pty Ltd 22,594,216 2.17%
Symington Pty Ltd 19,700,000 1.89%
HSBC Custody Nominees (Australia) Limited 16,314,861 1.56%
Mr Jules Christian Wilson 15,099,502 1.45%
Dr Alok Jhamb 15,000,000 1.44%
Mr Francis Xavier Parnis & Mrs Sally Jane Parnis 14,554,598 1.40%
Mr Michael Andrew Whiting & Mrs Tracey Anne Whiting 12,876,085 1.23%
Nurragi Investments Pty Ltd 12,850,000 1.23%
Mr Kevin John Day 12,500,000 1.20%
Mr Konstandinos Emmanouil 12,000,000 1.15%
Harold Cripps Holdings Pty Ltd 11,623,027 1.11%
Mr Anthony Bratton 10,986,115 1.05%
Jetosea Pty Ltd 10,000,000 0.96%
Aglub Investments Pty Ltd 9,945,731 0.95%
Ms Pharoth San & Mr Kaden San 9,500,000 0.91%
Gattenside Pty Ltd 9,033,037 0.87%
Queensland University Of Technology 8,087,010 0.78%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 201 84 170 986 811 2,252

Substantial Shareholders

No Substantial Shareholders for FTT in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.003 30 June
2019 $0.004 28 June
2018 $0.047 29 June
2017 $0.062 28 June
2016 $0.034 28 June
Page Icon
FTT Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.